Skip to main content
. 2017 Nov 28;9(17):13154–13166. doi: 10.18632/oncotarget.22743

Figure 2. Inhibition of DYRK1B by kinase inhibitor AZ191 or RNAi blocks proliferation in liposarcoma cell lines.

Figure 2

(A) Inhibition of cell proliferation after DYRK1B inhibitor AZ191 treatment of SW872 and SW982 cell lines as determined by the MTT assay. (B) Representative images of liposarcoma cells after treatment with increasing concentrations of DYRK1B inhibitor AZ191. Original magnification: 100×. Scale bar = 100 μm. (C) Representative images of liposarcoma cell colony formation after treatment with AZ191. (D) Inhibition of cell colony formation rate after AZ191 treatment of SW872 and SW982 cells determined by the clonogenic assay. (E) Inhibition of cell proliferation after DYRK1B siRNA transfection in SW872 and SW982 cell lines as determined by the MTT assay. (F) Inhibition of cell proliferation after DYRK1B esiRNA transfection in SW872 and SW982 cell lines as determined by the MTT assay. Data were shown as means ± S.D.

HHS Vulnerability Disclosure